Hikma has been told by the US Food and Drug Administration (FDA) to complete an additional clinical endpoint study to support its application for a generic version of GlaxoSmithKline’s Advair Diskus (fluticasone/salmeterol), following a dispute-resolution process with the US agency. Hikma had received an FDA complete response letter (CRL) in May 2017 indicating that its abbreviated new drug application (ANDA) was not ready for approval (Generics bulletin, 19 May 2017, page 1). And following disagreement with the FDA over the firm’s clinical endpoint study, Hikma took the matter to the agency’s disputeresolution process (Generics bulletin, 17 November 2017, page 13). “Upholding its original determination”, the FDA has insisted on an additional clinical endpoint study.
Hikma must add an Advair study
Hikma has been told by the US Food and Drug Administration (FDA) to complete an additional clinical endpoint study to support its application for a generic version of GlaxoSmithKline’s Advair Diskus (fluticasone/salmeterol), following a dispute-resolution process with the US agency. Hikma had received an FDA complete response letter (CRL) in May 2017 indicating that its abbreviated new drug application (ANDA) was not ready for approval (Generics bulletin, 19 May 2017, page 1). And following disagreement with the FDA over the firm’s clinical endpoint study, Hikma took the matter to the agency’s disputeresolution process (Generics bulletin, 17 November 2017, page 13). “Upholding its original determination”, the FDA has insisted on an additional clinical endpoint study.
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Generics Bulletin, or if you love it how it is, now is the time to have your voice heard.
Bringing in sales that translated to nearly $1.5bn last year, Japan’s Towa was feeling upbeat after a challenging few years, both for itself and the broader Japanese generics market. However, its financial guide for the next 12 months has left investors feeling cold.
Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.
More from Generics Bulletin
The EMA’s latest move towards a more streamlined process for biosimilar registration in Europe was the hottest topic at last week’s annual biosimilars conference held by Medicines for Europe in Amsterdam. Generics Bulletin discusses the new draft reflection paper and its significance for industry, reports on reactions from the event, and reveals the next steps unveiled by EMA officials.
Teva is charting a new course under its ‘Pivot to Growth’ strategy, providing a memory aid for investors to better understand the firm’s financials going into 2025.
Meitheal Pharmaceuticals said that its generic version of the GLP-1 agonist Victoza would be one of 22 planned launches during 2025, as the firm continues to build out its portfolio with the aid of its parent, Hong Kong King-Friend Industrial.